Skip to main
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc. has experienced a significant surge in share price, with an increase of over 400% in just one week, outperforming the broader biopharmaceutical index. The company's focus on allogeneic invariant natural killer T (iNKT) cell therapies offers a unique value proposition due to their scalable, cost-effective manufacturing capabilities and the ability to retain crucial tumor-homing and immunomodulatory features. Moreover, the anticipated updates from upcoming clinical trials, including the Phase 2 gastric trial for agenT-797, provide potential for further advancements and support a positive outlook for future investments.

Bears say

MiNK Therapeutics faces significant financial risks that contribute to a negative outlook, primarily stemming from potential safety signals and lower-than-expected efficacy in its clinical programs, which could jeopardize future developmental milestones. Additionally, the company may encounter fierce commercial competition, regulatory challenges, and substantial financing needs, with projections indicating that approximately $55 million in further financing will be necessary by 2038 to maintain operations until mid-2025. The company also confronts a de-listing risk if its share price falls below $1, alongside concerns regarding the adequacy of its intellectual property protection, all of which could adversely impact investor confidence.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.